Mr. Madhukar worked for 5 years in a multi-commodity trading company after graduating from a reputed B-School. He then resigned from his job and started an online garment export business. For his business Madhukar used Rs. 8,00,000/- of his own savings and borrowed Rs. 12,00,000/- from a private sector bank in April, the beginning month of the financial year. Meanwhile, RBI eased the repo rate in May and banks passed on the benefits to the borrowers. As a result, Madhukar borrowed an additional Rs. 9,00,000/- after 4 months at an interest rate that is 10% lower than his earlier borrowing interest rate. If the total interest paid by Madhukarat at the end of that year on both the loans is Rs. 1,39,200/-, what is the interest rate per annum on first borrowing?

Mr. Madhukar worked for 5 years in a multi-commodity trading company after graduating from a reputed B-School. He then resigned from his job and started an online garment export business. For his business Madhukar used Rs. 8,00,000/- of his own savings and borrowed Rs. 12,00,000/- from a private sector bank in April, the beginning month of the financial year. Meanwhile, RBI eased the repo rate in May and banks passed on the benefits to the borrowers. As a result, Madhukar borrowed an additional Rs. 9,00,000/- after 4 months at an interest rate that is 10% lower than his earlier borrowing interest rate. If the total interest paid by Madhukarat at the end of that year on both the loans is Rs. 1,39,200/-, what is the interest rate per annum on first borrowing? Correct Answer 8 Percent

Related Questions

In the question below, are given a statement followed by three courses of actions numbered I, II and III. On the basis of the information given, you have to assume everything in the statement to be true, and then decide which of the suggested courses of action logically follow(s) for pursuing. Statement: India’s pharmaceutical sector is now popping out from a shell and making a remarkable recovery. Actually, it has been facing several regulatory challenges in the forms of a recast of foreign direct investment (FDI) policy, pricing policy in the US generics market, patent protection, regulatory approvals and compulsory licensing. Also limited new product launches in the generics space, GST introduction and higher costs associated with regulatory compliance have hurt the sector. Courses of action: I. The government has been engrossed more in policy making and taking resilient decisions for the concerns of the pharma industry. Recently, the government proposed to introduce a new price index for pharmaceutical products, which would serve as a benchmark for determining prices of all medicines sold in the country. II. Meanwhile, pharma companies’ constant investments in R&D have enabled them to develop a basket of robust products for markets across the world. In international markets, pricing pressure on generics sold in the US has eased and this is likely to support the sector. III. Domestic pharma sales grew to Rs. 10,583 crore in May 2018 from Rs. 9,549 crore in the same month last year. The recent clearance by the US Food and Drug Administration to Sun Pharma’s manufacturing plant at Halol in Gujarat brings to an end a two-year import ban it had imposed on the company over quality issues. This is likely to increase sales for the company.